Metagenomi Therapeutics develops gene editing tools and genetic medicines for patients, based in Emeryville, California. MGX reports earnings on Tue, Nov 10, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 11 | Wells Fargo | Maintained | Buy | |
| Jul 7 | Chardan Capital | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in MGX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MGX is in one of them and how their past MGX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MGX in an article yet. Here's the latest on the wider market.
About Metagenomi Therapeutics
Metagenomi Therapeutics is a biotechnology company based in Emeryville, California, that develops gene editing tools and genetic medicines. It builds its tools from a large database of genetic material collected from the natural environment, and uses them to design systems that can correct or change specific genes. Its main program, MGX-001, is being developed as a treatment for hemophilia A, a bleeding disorder. The company also works with pharmaceutical partners on programs for cardiometabolic diseases, and its target patients are people with genetic diseases.
- Headquarters
- Emeryville, CA